• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, H1 2013 - Product Image

Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, H1 2013

  • Published: May 2013
  • 23 pages
  • Global Markets Direct

Aneurysmal Subarachnoid Hemorrhage (SAH) – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Aneurysmal Subarachnoid Hemorrhage (SAH), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aneurysmal Subarachnoid Hemorrhage (SAH). Aneurysmal Subarachnoid Hemorrhage (SAH) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Aneurysmal READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Aneurysmal Subarachnoid Hemorrhage (SAH) Overview
Therapeutics Development
An Overview of Pipeline Products for Aneurysmal Subarachnoid Hemorrhage (SAH)
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics under Development by Companies
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics – Products under Development by Companies
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics Development
Aneurysmal Subarachnoid Hemorrhage (SAH) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Molecule Type
Drug Profiles
nimodipine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tiopronin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics – Drug Profile Updates
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics – Discontinued Products
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics - Dormant Products
Aneurysmal Subarachnoid Hemorrhage (SAH) – Product Development Milestones
Featured News & Press Releases
Oct 04, 2010: Edge Provides Update On NimoGel
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Aneurysmal Subarachnoid Hemorrhage (SAH), H1 2013
Products under Development for Aneurysmal Subarachnoid Hemorrhage (SAH) – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics – Drug Profile Updates
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics – Discontinued Products
Aneurysmal Subarachnoid Hemorrhage (SAH) Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Aneurysmal Subarachnoid Hemorrhage (SAH), H1 2013
Products under Development for Aneurysmal Subarachnoid Hemorrhage (SAH) – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Mid Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013 15

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos